WorldHeart Gaining Access To U.S. VAD Market Via Edwards' Novacor
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart will gain immediate access to the U.S. left ventricular assist device market through Edwards Lifesciences' Novacor ventricular assist system under a definitive licensing agreement announced May 25.
You may also be interested in...
FDA-Cleared Access Program Bodes Well For HeartMate Trial, Thoratec Says
FDA's decision allowing Thoratec to make the HeartMate VE battery-powered left ventricular assist system available to patients outside its IDE trial indicates preliminary survival data are "very encouraging," the company says.
FDA-Cleared Access Program Bodes Well For HeartMate Trial, Thoratec Says
FDA's decision allowing Thoratec to make the HeartMate VE battery-powered left ventricular assist system available to patients outside its IDE trial indicates preliminary survival data are "very encouraging," the company says.
Thoratec Seeks Therapeutic VAD, Others Aim For Alternative-To-Transplant
Thoratec plans to file a PMA supplement for a therapeutic recovery indication for the Thoratec ventricular assist device (VAD) by year-end.